LSLucille Sebastian

Lucille Sebastian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucille Sebastian has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From exclusion to engagement and enrolment: single institutional experience of recruiting Aboriginal and Torres Strait Islander peoples for a genomic sequencing study

    by Michail Charakidis, Halli Waran, Yat Ming Lau, David Thomas, Lucille Sebastian, Maree Toombs

    Indigenous peoples remain under‐represented in genomic research and clinical trials. This reflects historical exclusion, mistrust and health system barriers. In this article, we describe a single Australian institution's experience in improving engagement and enrolment of Aboriginal and Torres Strait Islander patients in a cancer genomic sequencing study. We reflect on challenges related to rapport, consent and enrolment and outline practical strategies including relationship‐building, targeted resources and a tailored enrolment pathway. We contend that equitable participation in genomic research requires sustained, trust‐based and culturally specific engagement, rather than reliance on purely technical or procedural solutions.

  • Open Access

    Supplementary Tables 1-3 from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

    by Gregory M. Cote, Mason Aberoumand, Edwin Choy, Lucille Sebastian, Emanuele Mazzola, Peter Grimison, Priscilla Merriam, Mandy Ballinger, Subotheni Thavaneswaran, Frank Lin, et al.

  • Open Access

    Data from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

    by Gregory M. Cote, Mason Aberoumand, Edwin Choy, Lucille Sebastian, Emanuele Mazzola, Peter Grimison, Priscilla Merriam, Mandy Ballinger, Subotheni Thavaneswaran, Frank Lin, et al.

    Purpose:Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies.Patients and Methods:Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1.Results:Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data.Conclusions:Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.See related commentary by Chen, p. 2130

  • A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma

    by Gregory M. Cote, Mason Aberoumand, Edwin Choy, Lucille Sebastian, Emanuele Mazzola, Peter Grimison, Priscilla Merriam, Mandy Ballinger, Subotheni Thavaneswaran, Frank Lin, et al.

    Purpose: Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies. Patients and Methods: Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1. Results: Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data. Conclusions: Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity. See related commentary by Chen, p. 2130